UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
XCUR
Exicure, Inc.
There isn't enough reported data to score XCUR yet.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
XCUR Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Strong |
XCUR's balance sheet is currently strong, but its profitability is under pressure. There isn't enough data to rate its revenue and cash flow.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
XCUR PE Valuation
XCUR has no meaningful PE right now: it lost money over the past year.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
XCUR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect XCUR's losses to grow, with revenue growing.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over XCUR on earnings quality, reporting a profit while its opponent remains loss making.
XCUR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.34 | +$2.48 |
| Q1 2026 | -$1.57 | +$2.19 |
| Q4 2025 | -$0.79 | +$3.96 |
| Q3 2025 | -$3.64 | -$1.62 |
| Q2 2025 | -$3.82 | +$0.68 |
| Q1 2025 | -$3.76 | +$3.79 |
| Q4 2024 | -$4.75 | +$5.80 |
| Q3 2024 | -$2.02 | -118% |
XCUR is still losing money, but far less than before: $1.34 per share over the past year, against $82.50 at its worst in mid-2021.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over XCUR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH's operating margin was 5.8% last quarter, up 2 points from the same quarter a year ago.
XCUR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2022 | $21.8M | +928% |
| Q2 2022 | $2.5M | +3028% |
| Q1 2022 | $2.6M | +157% |
| Q4 2021 | $2.1M | +1413% |
| Q2 2021 | $79K | -98% |
| Q1 2021 | $997K | -89% |
| Q4 2020 | $140K | -55% |
| Q3 2020 | $2.4M | +364% |
XCUR's revenue is shrinking: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2024 | -167% | N/A |
| Q4 2022 | 85% | +720 points |
| Q3 2022 | -258% | N/A |
| Q2 2022 | -303% | +17244 points |
| Q1 2022 | -302% | +918 points |
| Q4 2021 | -635% | +8265 points |
| Q2 2021 | -17547% | -17456 points |
| Q1 2021 | -1219% | -1225 points |
XCUR's operating margin was −167% last quarter, up 134 points from the same quarter a year ago.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
XCUR has the stronger cash trend. Its trailing FCF is up 68% versus its history, compared with UNH at up 5.2%.
XCUR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$1.1M | +$456K |
| Q4 2025 | -$934K | -$89K |
| Q3 2025 | -$3.4M | -$3M |
| Q1 2025 | -$1.6M | -$1.1M |
| Q4 2024 | -$845K | -$29K |
| Q3 2024 | -$449K | +$963K |
| Q2 2024 | -$1.2M | +$3.6M |
| Q1 2024 | -$450K | +$2.9M |
XCUR has burned cash in almost every quarter: −$7M over the past year, against −$3M the year before.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over XCUR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
XCUR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +25 shares |
| 1 year | +0.9% | +56.2K shares |
| 3 years | +278% | +4.7M shares |
| 5 years | +996% | +5.8M shares |
| Available history | +1379% | +5.9M shares |
XCUR has 6M diluted shares, up 0.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2021 | $9,000 |
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
XCUR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2023 | -0.2x | Net Cash |
| Q2 2023 | -0.6x | Net Cash |
| Q1 2023 | -4.0x | Net Cash |
XCUR has more cash than debt.
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
XCUR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 31.4 | Neutral |
| Stochastic | 20.3 | Neutral |
XCUR's weekly RSI is 31 (neutral) and its Stochastic is 20 (neutral).
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
XCUR PE vs Healthcare Sector
| Metric | XCUR | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
XCUR has no meaningful PE right now: it lost money over the past year.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over XCUR on trend strength, trading above more of its moving averages.
XCUR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.08 | 1.9% below |
| 20 week MA | $1.31 | 19% below |
| 50 week MA | $3.02 | 65% below |
| 100 week MA | $5.82 | 82% below |
| 200 week MA | $5.12 | 79% below |
XCUR is in a downtrend: it's below all five of its weekly moving averages, and 79% below its 200-week average.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over XCUR on returns for 2026, with the stronger performance.
XCUR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $417.0 | $289.5 | -31% |
| 2021 | $289.5 | $32.6 | -89% |
| 2022 | $32.6 | $6.40 | -80% |
| 2023 | $6.40 | $2.90 | -55% |
| 2024 | $2.90 | $17.6 | +506% |
| 2025 | $17.6 | $5.99 | -66% |
| 2026 YTD | $5.99 | $1.06 | -82% |
XCUR's yearly returns have swung widely, from +506% in 2024 to −89% in 2021. It's down 82% so far in 2026.